<?xml version="1.0" encoding="UTF-8"?>
<p>KEAL has privately or via his employer been a consultant during the two last years for Chugai Pharmaceutical, Bioniz Therapeutics, Interexon Actobiotics, Amyra Biotech AG and Dr. Falk Pharma GMBH. LMS has privately or via his employer been a consultant during the two last years for Amagma Therapeutics, Chugai Pharmaceutical, Bioniz Therapeutics, Interexon Actobiotics, UCB Biopharma, Merck and GSK. The other authors declare no conflicts of interest.</p>
